Toronto, ON – November 19, 2025 – Grey Matter Neurosciences, a leader in focused-ultrasound-based neurotechnologies and brain-computer interfaces, today announced the appointment of four distinguished experts to its Scientific Advisory Board. These appointments strengthen Grey Matter’s commitment to innovation and evidence-based development as it advances its next generation of transcranial neuromodulation solutions to clinical application.
The newly appointed members bring extensive experience across neuropsychiatric clinical research and transcranial and invasive deep brain stimulation. They will provide strategic guidance on research initiatives, clinical validation, and the integration of emerging technologies into Grey Matter’s product pipeline. Additional members may be added in the coming months.
“We are honoured to welcome this exceptional group of scientists and clinicians to our Scientific Advisory Board,” said Dr. Jeffrey Coull, Founder and Chief Executive Officer of Grey Matter Neurosciences. “Their insights and diverse expertise will be invaluable as we accelerate the development of transformative focused-ultrasound-based technologies that improve outcomes for patients with age-related disease of the brain.”
New Scientific Advisory Board members:
- Nir Lipsman, MD, PhD [Chair] – Neurosurgeon, Harquail Chair in Neuromodulation, University of Toronto and Sunnybrook Health Sciences Centre; Chief, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre
- Joan Camprodon-Gimenez, MD, PhD, MPH – Neuropsychiatrist, Chief, Division of Neuropsychiatry and Director, Laboratory for Neuropsychiatry & Neuromodulation, Mass General Brigham; Associate Professor of Psychiatry, Harvard Medical School
- Renana Eitan, MD – Psychiatrist and Neuroscientist, Chair of Psychiatry at Tel Aviv Medical Center (Ichilov)
- Noah Philip, MD – Psychiatrist, Section Chief, Psychiatric Neuromodulation, VA Providence; Professor of Psychiatry and Human Behavior, Alpert Medical School of Brown University
These appointments come as Grey Matter finalizes it’s first minimum viable product, the conformal transcranial LIFU system, and prepares to initiate a first-in-human clinical study.
About Grey Matter Neurosciences
Grey Matter Neurosciences is a Toronto-based medical technology advancing novel devices, brain-computer interfaces and drug-device combinations to treat age-related diseases of the brain. Founded in 2024, the company is built on groundbreaking transcranial focused ultrasound technology developed at Sunnybrook Research Institute. To date, Grey Matter has secured nearly $20M in equity-based and non-dilutive funding. For more information, please see www.greymatterneurosciences.com.
Media Contact
Jeffrey Coull
Founder and CEO
Grey Matter Neurosciences
info@greymatterneurosciences.com